Brentuximab vedotin in patients with Hodgkin Lymphoma and a failed allogeneic stem cell transplantation: Results from a named patient program at four italian centers

Carmelo Carlo-Stella, Francesca Rcci, S. Erena Dalto, Rita Mazza, Michele Malagola, Francesca Patriarca, Simonetta Viviani, Domenico Russo, Laura Giordano, Luca Castagna, Paolo Corradini, Armando Santoro

Research output: Contribution to journalArticle

Abstract

Background. Brentuximab vedotin (BV) has demonstrated an extraordinary efficacy in heavily pretreated classical Hodgkin lymphoma (cHL) patients, targeting CD30-positive cells; however, limited data have been reported on the efficacy of BV in cHL patients failing allogeneic stem cell transplantation (allo-SCT).The aim of this study was to retrospectively evaluate the efficacy and safety of BV in a multicenter setting of cHL relapsing or progressing after allo-SCT. Methods. Sixteen BV-na¨ve patients with recurrent cHL after allo-SCT were included in a compassionate use program and treated with intravenous BV at the dose of 1.8 mg/kg of body weight every 3 weeks for a maximum of 16 cycles. Results. The objective response rate was 69%. Five patients (31%) had complete remission, and 6 (37%) had partial remission. Stable disease was observed in 4 patients (25%), and progressive disease was observed in 1 (6%). After median follow-up of 26 months (range: 5-30 months), median progression-free survival (PFS), overall survival (OS), and duration of response were 7, 25, and 5 months, respectively. The 2-year PFS and OS were 20% and 61%, respectively. Grade 3-4 hematological adverse events included anemia (15%), thrombocytopenia (12%), and neutropenia (18%). Grade 3 peripheral sensory neuropathy occurred in 2 patients (12%). Conclusion. BV therapy is an effective and safe approach for achieving transient disease control in cHL patients with failed allo-SCT. To improve disease control, future studies should explore the combination of BV with targeted agents.

Original languageEnglish
Pages (from-to)323-328
Number of pages6
JournalThe oncologist
Volume20
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Keywords

  • Allogeneic stem cell transplantation
  • Brentuximab vedotin
  • CD30
  • Relapsed or refractory Hodgkin lymphoma
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Brentuximab vedotin in patients with Hodgkin Lymphoma and a failed allogeneic stem cell transplantation: Results from a named patient program at four italian centers'. Together they form a unique fingerprint.

Cite this